Business
Adidas sneakers
Sherwood News

Buzzy sneakers are kicking Adidas in the right direction

The sportswear giant is back in the green

Adidas appears to be back on track following some recent trip-ups — largely owing to an uptick in sneaker sales, with Sambas and Gazelles filling the shoe-shaped gap left after the company parted ways with Kanye West and his once-hyped Yeezy brand.

After posting its first annual loss in more than 30 years in March, citing high inventories as a cause of the sales slump, Adidas’ Q2 report, published today, provided a more promising outlook. Indeed, the German sportswear behemoth made a net profit of €206 million (~$223 million) in the three months to June 30 — up 117% from the same period a year ago — with revenues from its footwear segment alone climbing 17%.

In addition to reducing its inventory problem by €1 billion in the past year, the success of Adidas’ marketing efforts at major sporting events like the Paris Olympics has also helped to boost jersey and other athletic apparel sales.

Samba season

But, as any sneakerhead worth their salt will know, there's a lot of money to be made from zeitgeist-capturing footwear. The dissolution of Adidas’ deal with rapper Kanye West in 2022 drew the curtain on an incredibly lucrative partnership for both parties. In the aftermath of the Yeezy discontinuation, Adidas sales plunged 16% in North America in 2023, despite remaining relatively flat in other regions.

Recently, though, a new fleet of Adidas footwear has been capturing the attention of the fashion (and wider) world, at least if Google searches are anything to go by. Sambas, Gazelles, and Campuses have all hit new internet interest peaks in 2024, as mainstream tastes continue to shift in favor of more classic silhouettes.

Given the fickle nature of fashion, though, Adidas likely already has a team working to deliver its next smash hit, after the Samba was named 2023's “shoe of the year” and ex-UK prime minister Rishi Sunak apologized for “ruining” the sneakers for fans back in April.

More Business

See all Business
The Sphere In Las Vegas

Washington D.C. looks set to get America’s second Sphere

Revenue for the Las Vegas version of the big orb has soared, but the sphere is still a money pit.

business

Ford reportedly in talks to buy hybrid vehicle batteries from Chinese auto giant BYD

Detroit’s Ford and China’s BYD are said to be in ongoing talks to partner on an agreement that would see Ford buy hybrid vehicle batteries from BYD, according to reporting from The Wall Street Journal.

The report comes just days after President Trump toured a Ford factory in Michigan and implied openness to Chinese automakers coming to the US.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

Still life of Ozempic and Wegovy with weight scale.

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs.

Handshake

Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.